Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
Verastem Oncology dosed the first patient in the TARGET-D 201 Phase 2 registration-directed trial of VS-7375 for KRAS G12D-mutated metastatic pancreatic cancer. The trial evaluates VS-7375 at 900 mg daily as monotherapy and in combination with cetuximab for second-line treatment, with an additional cohort assessing the combination in the frontline setting.
Key figures
- Drug Name
- VS-7375
- Phase Of Trial
- Phase 2
- Dose mg
- 900
- Metastatic pancreatic dx annual us
- 30000
- Kras g12d prevalence pancreatic pct
- 40
- Metastatic pancreatic dx annual global
- 240000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.